Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?

Treatment of relapsed/refractory diffuse large B‐cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR‐T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET‐derived parameters, the report of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisselbrecht, Christian, Sibon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086831/
https://www.ncbi.nlm.nih.gov/pubmed/36120952
http://dx.doi.org/10.1111/bjh.18468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086831/
https://www.ncbi.nlm.nih.gov/pubmed/36120952
http://dx.doi.org/10.1111/bjh.18468

Ejemplares similares